A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance from the laboratory to the clinic.
View details for DOI 10.3727/096368909X470883
View details for Web of Science ID 000271253200002
View details for PubMedID 19796499